Antibiotic compostions and methods for using same
Compositions including a quinolone component in an amount effective as an antibiotic when the composition is placed in a mammalian eye, and a carrier component in an amount effective to act as a carrier for the quinolone component are provided. The present compositions are substantially free of other components effective as preservatives. Preferably the quinolone component has fungistatic activity. In one very useful embodiment, the compositions include a NSAID component in an amount effective to reduce inflammation or pain when the composition is placed in a mammalian eye. Methods of using the present compositions, for example, to resolve microbial infections and/or to reduce inflammation and/or pain in a mammalian eye are included within the scope of the present invention.
1 - 35 . (canceled)
36 . An ophthalmically acceptable composition comprising from about 0.15% to about 1.1% of a quinolone antibiotic present in a therapeutically effective amount, wherein said composition contains substantially no additional components which are effective as preservatives, is self-preserved, and is suitable for topical application to the eye.
37 . The composition of claim 36 wherein said quinolone is a halogenated quinolone antibiotic.
38 . The composition of claim 36 wherein the quinolone is a fluorinated quinolone antibiotic.
39 . The composition of claim 36 in a liquid form.
40 . The composition of claim 36 in a gel form.
41 . The composition of claim 36 in a solid form.
42 . The composition of claim 36 which contains a water soluble polymer.
43 . The composition of claim 42 wherein said water soluble polymer is a cellulose derivative.
44 . The composition of claim 36 , wherein said composition contains sufficient preservative efficacy to pass the U.S. Preservative Efficacy Test.
45 . A method of treating an ocular infection without substantial irritation caused by added preservatives comprising administering to a mammalian eye an ophthalmically acceptable solution comprising from about 0.15% to about 1.1% of a quinolone antibiotic present in a therapeutically effective amount, wherein said composition contains substantially no additional components which are effective as preservatives, and is self-preserved.
46 . The method of claim 45 wherein the composition comprises a water soluble polymer.
47 . The method of claim 46 wherein the water soluble polymer is a cellulose derivative.
48 . The method of claim 45 wherein the quinolone antibiotic is a halogenated quinolone.
49 . The method of claim 48 wherein the quinolone antibiotic is a fluorinated quinolone.
50 . The method of claim 45 wherein said composition contains sufficient preservative efficacy to pass the U.S. Preservative Efficacy Test.
51 . The method of claim 45 wherein said composition is administered topically.